Use of Sodium-Glucose Transport Protein 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors in Patients with MASLD in a Real-World Setting is Associated with Lower All-Cause Mortality

被引：0

作者：

Hurr, Sophia ^{[1
]}

Munoz, Breda ^{[2
]}

Mospan, Andrea Rossi. ^{[2
]}

Roden, Michael ^{[3
]}

Cusi, Kenneth ^{[4
]}

Barritt, Alfred S. ^{[5
]}

机构：

[1] Univ North Carolina Chapel Hill, Sch Med, Chapel Hill, NC USA

[2] Target RWE, Durham, NC USA

[3] Heinrich Heine Univ, Dusseldorf, Nordrhein Westf, Germany

[4] Univ Florida, Coll Med, Gainesville, FL USA

[5] UNC, Chapel Hill, NC USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期

关键词：

D O I：

10.14309/01.ajg.0001036124.61521.5f

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S1689

引用

页码：S1231 / S1232

页数：2

共 50 条

[1] Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real-world evidence study
Sung, Hui-Lin
Hung, Chuan-Yu
Tung, Yu-Chun
Lin, Chih-Chung
Tsai, Tung-Han
Huang, Kuang-Hua
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2024, 40 (03)
[2] Effect of sodium-glucose transport protein 2 inhibitors on all-cause mortality in patients with gout: A multi-center cohort study
Chan, Shu-Yen
Ma, Kevin Sheng-Kai
METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 153
[3] Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study
Chung, Yoo-Ri
Ha, Kyoung Hwa
Lee, Kihwang
Kim, Dae Jung
PLOS ONE, 2019, 14 (10):
[4] Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis
Zheng, Sean L.
Roddick, Alistair J.
Aghar-Jaffar, Rochan
Shun-Shin, Matthew J.
Francis, Darrel
Oliver, Nick
Meeran, Karim
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (15): : 1580 - 1591
[5] Sodium-Glucose Cotransporter-2 Inhibitors Are Associated With Lower Risks of Hospitalization for Heart Failure and All-Cause Mortality in Patients With Diabetes Mellitus and Cancer
Chiang, Cho Han
Chiang, Cho Hung
Chiang, Cho Hsien
Ma, Kevin
Peng, Chun-Yu
Hsia Yuanping
Horng, Chuan-Sheng
Chen, Cheng-Ying
Chang, Yu-Cheng
See, Xin Ya
Chen, Yuan-Jen
Wang, Shih-Syuan
Abreu, Giselle A. Suero
Peterson, Linda R.
Thavendiranathan, Paaladinesh
Armand, Philippe
Peng, Cheng-Ming
Shiah, Her-Shyong
Neilan, Tomas G.
CIRCULATION, 2022, 146
[6] All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes
Fu-Shun Yen
Jen-Huai Chiang
Chii-Min Hwu
Yu-Hsin Yen
Boniface J. Lin
James Cheng-Chung Wei
Chih-Cheng Hsu
BMC Endocrine Disorders, 19
[7] Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis
Takahashi, Hirokazu
Asakawa, Keiko
Kosakai, Yoshinori
Lee, Takumi
Rokuda, Mitsuhiro
DIABETES OBESITY & METABOLISM, 2024, 26 (03): : 997 - 1007
[8] Changes in prescribing of sodium-glucose co-transporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in Singapore
Goh, Louise G. H.
Sun, Jiandong
Ng, Kwong
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 141 - 141
[9] All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes
Yen, Fu-Shun
Chiang, Jen-Huai
Hwu, Chii-Min
Yen, Yu-Hsin
Lin, Boniface J.
Wei, James Cheng-Chung
Hsu, Chih-Cheng
BMC ENDOCRINE DISORDERS, 2019, 19 (1)
[10] Sodium-glucose Cotransporter-2 Inhibitors as Modulator of Dipeptidyl Peptidase-4 in Diabetes
Rafeeq, Misbahuddin M.
Haque, Shahnaz
Sain, Ziaullah M.
Alzamami, Ahmad
Alturki, Norah A.
Mashraqi, Mutaib M.
Alghamdi, Youssef Saeed
Alniwaider, Rashed Ahmed
Patel, Ayyub
INDIAN JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH, 2021, 55 (04) : 1008 - 1016

← 1 2 3 4 5 →